Specifically, siRNA-mediated interventions [48–50] designed to inhibit Wnt/β-catenin signaling, NIK/non-canonical NF-κB, and/or NRF2 expression, individually or in combination, could potentially prevent the transition from NASH to HCC, and improve the efficacy of existing HCC treatments. The gene discussed is MAP3K14; the disease is hepatocellular carcinoma.